TXG 10-Q report for 2026-03-31

TXG is 10x Genomics, Inc., a Healthcare equity in Health Information Services, developing tools and consumables for single-cell and spatial genomics research.

TXG 10-Q report for 2026-03-31 txg-20260331 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended  March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number:  001-39035 10x Genomics, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5614458 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6230 Stoneridge Mall Road Pleasanton , California 94588 (Address of principal executive offices) (Zip Code) ( 925 ) 401-7300 (Registrant’s telephone number, including area code) N/A (Former name, former address and former fiscal year, if changed since last report) _____________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒     No   ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes ☒     No   ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   ☐    No  ☒ As of April 30, 2026, the registrant had 116,877,317 shares of Class A common stock, $0.00001 par value per share, outstanding and 10,078,872 shares of Class B common stock, $0.00001 par value per share, outstanding. Table of Contents Table of Contents Page PART I. FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders’ Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3. Quantitative and Qualitative Disclosures about Market Risk 21 Item 4. Controls and Procedures 21 PART II. OTHER INFORMATION 22 Item 1. Legal Proceedings 22 Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 5. Other Information 22 Item 6. Exhibits 23 Signatures 24 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safe harbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies, acquisition of Scale Biosciences Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3. Quantitative and Qualitative Disclosures about Market Risk 21 Item 4. Controls and Procedures 21 PART II. OTHER INFORMATION 22 Item 1. Legal Proceedings 22 Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 5. Other Information 22 Item 6. Exhibits 23 Signatures 24 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safe harbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies, acquisition of Scale Biosciences, Inc., results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, plans and expectations regarding entering the clinical and diagnostic markets, the timing and outcome of regulatory filings and approvals, performance and benefits of our products and services, business trends and other information. These statements are based on management’s expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.’s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Genomics, Inc. disclaims any obligation to update any published forward-looking statements except as required by law. The material risks, uncertainties and other factors that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ from those indicated by the forward-looking statements made include those described in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Our periodic filings are accessible on the U.S. Securities and Exchange Commission's (“SEC”) website at www.sec.gov. Although we believe the expectations reflected in the forward-looking statements are reasonable, new risks and uncertainties may emerge, and it is not possible for us to predict their impact on the forward-looking statements contained in this Quarterly Report. Moreover, the information the forward-looking statements are based upon may be limited or incomplete, and may not be based upon all potentially relevant information. We cannot guarantee future events, circumstances, results, performance or achievements. In light of the foregoing, investors are urged not to place undue reliance on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our,” “the Company,” “10x” and similar references refer to 10x Genomics, Inc. and its subsidiaries. 1 Table of Contents Channels for Disclosure of Information Investors and others should note that we may announce material information to the public through filings with the SEC, our website (https://www.10xGenomics.com), press releases, public conference calls, public webcasts and our social media accounts (https://www.linkedin.com/company/10xgenomics, https://X.com/10xGenomics, https://www.facebook.com/10xGenomics, https://bsky.app/profile/10xgenomics.bsky.social and https://www.youtube.com/@10xGenomics_). We use these channels to communicate with our customers and the public about the Company, our products, our services, our financial results, business developments and other matters. We encourage our investors, the media and others to review the information disclosed through such channels as such information could be deemed to be material information. The information on such channels, including on our website and our social media accounts, is not incorporated by reference in this Quarterly Report and shall not be deemed to be incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Please note that this list of disclosure channels may be updated from time to time. 2 Table of Contents 10x Genomics, Inc. PART I—FINANCIAL INFORMATION Item 1.    Financial Statements. 10x Genomics, Inc. Condensed Consolidated Balance Sheets (In thousands) March 31, 2026 December 31, 2025 (Unaudited) (Note 1) Assets Current assets: Cash and cash equivalents $ 490,285 $ 473,966 Marketable securities 49,563 49,443 Accounts receivable, net 39,031 47,013 Other receivables 17,106 35,480 Inventory 53,487 56,341 Prepaid expenses and other current assets 20,261 22,208 Total current assets 669,733 684,451 Property and equipment, net 220,591 226,711 Operating lease right-of-use assets 58,390 60,450 Goodwill 4,511 4,511 Intangible assets, net 59,910 62,329 Other noncurrent assets 2,624 2,913 Total assets $ 1,015,759 $ 1,041,365 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 17,425 $ 12,733 Accrued compensation and related benefits 21,506 42,500 Accrued expenses and other current liabilities 33,680 39,971 Deferred revenue 24,342 23,902 Operating lease liabilities 11,330 10,985 Contingent consideration, current 5,315 23,363 Total current liabilities 113,598 153,454 Contingent consideration, noncurrent 1,222 1,237 Operating lease liabilities, noncurrent 70,059 73,376 Deferred revenue, noncurrent 10,138 10,501 Other noncurrent liabilities 6,418 6,471 Total liabilities 201,435 245,039 Commitments and contingencies (Note 4) Stockholders’ equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 2,338,269 2,306,690 Accumulated deficit ( 1,524,061 ) ( 1,510,591 ) Accumulated other comprehensive income 114 225 Total stockholders’ equity 814,324 796,326 Total liabilities and stockholders’ equity $ 1,015,759 $ 1,041,365 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended March 31, 2026 2025 Products and services revenue $ 149,896 $ 137,823 License and royalty revenue 947 17,060 Revenue 150,843 154,883 Cost of products and services revenue 44,665 49,438 Gross profit 106,178 105,445 Operating expenses: Research and development 56,847 64,245 Selling, general and administrative 66,377 89,728 Gain on settlement — ( 9,200 ) Total operating expenses 123,224 144,773 Loss from operations ( 17,046 ) ( 39,328 ) Other income (expense): Interest income 5,014 3,686 Other income (expense), net ( 815 ) 2,136 Total other income 4,199 5,822 Loss before provision for income taxes ( 12,847 ) ( 33,506 ) Provision for income taxes 623 852 Net loss $ ( 13,470 ) $ ( 34,358 ) Net loss per share, basic and diluted $ ( 0.10 ) $ ( 0.28 ) Weighted-average shares used to compute net loss per share, basic and diluted 128,291,153 122,606,091 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (In thousands) Three Months Ended March 31, 2026 2025 Net loss $ ( 13,470 ) $ ( 34,358 ) Other comprehensive income (loss), net of tax: Unrealized losses on available-for-sale marketable securities ( 22 ) ( 20 ) Foreign currency translation adjustment ( 89 ) 146 Other comprehensive income (loss), net of tax ( 111 ) 126 Comprehensive loss $ ( 13,581 ) $ ( 34,232 ) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 5 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (In thousands, except share data) Common Stock Additional  Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance as of December 31, 2025 127,691,329 $ 2 $ 2,306,690 $ ( 1,510,591 ) $ 225 $ 796,326 Issuance of Class A common stock related to equity awards 900,221 —  273 —  —  273 Issuance of Class A common stock for settlement of contingent consideration 396,584 —  8,699 —  —  8,699 Stock-based compensation —  —  22,607 —  —  22,607 Net loss —  —  —  ( 13,470 ) —  ( 13,470 ) Other comprehensive loss —  —  —  —  ( 111 ) ( 111 ) Balance as of March 31, 2026 128,988,134 $ 2 $ 2,338,269 $ ( 1,524,061 ) $ 114 $ 814,324 Common Stock Additional  Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance as of December 31, 2024 122,291,837 $ 2 $ 2,177,672 $ ( 1,467,047 ) $ ( 493 ) $ 710,134 Issuance of Class A common stock related to equity awards 841,913 —  422 —  —  422 Stock-based compensation —  —  30,571 —  —  30,571 Net loss —  —  —  ( 34,358 ) —  ( 34,358 ) Other comprehensive income —  —  —  —  126 126 Balance as of March 31, 2025 123,133,750 $ 2 $ 2,208,665 $ ( 1,501,405 ) $ ( 367 ) $ 706,895 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (In thousands) Three Months Ended March 31, 2026 2025 Operating activities: Net loss $ ( 13,470 ) $ ( 34,358 ) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 22,642 31,076 Depreciation and amortization 9,957 8,022 Non-cash lease expense 1,953 1,792 Fair value adjustments on contingent consideration ( 57 ) — Asset and lease impairment charges — 114 Other ( 193 ) ( 575 ) Changes in operating assets and liabilities: Accounts receivable 7,980 35,325 Other receivables 18,129 — Inventory 2,702 8,058 Prepaid expenses and other current assets 1,945 ( 5,530 ) Other noncurrent assets 282 2,314 Accounts payable 4,782 ( 2,547 ) Accrued compensation and other related benefits ( 20,956 ) ( 11,745 ) Deferred revenue 77 347 Accrued contingent consideration and assumed liabilities ( 613 ) — Accrued expenses and other current liabilities ( 6,136 ) 4,329 Operating lease liability ( 2,854 ) ( 2,631 ) Other noncurrent liabilities ( 50 ) 360 Net cash provided by operating activities 26,120 34,351 Investing activities: Purchases of property and equipment ( 1,597 ) ( 1,893 ) Purchases of marketable securities ( 24,714 ) — Proceeds from maturities of marketable securities 25,000 — Net cash used in investing activities ( 1,311 ) ( 1,893 ) Financing activities: Issuance of common stock from exercise of stock options 273 422 Payment of contingent consideration ( 8,690 ) — Net cash provided by (used in) financing activities ( 8,417 ) 422 Effect of exchange rates changes on cash and cash equivalents ( 73 ) 114 Net increase in cash and cash equivalents 16,319 32,994 Cash and cash equivalents at beginning of period 473,966 344,067 Cash and cash equivalents at end of period $ 490,285 $ 377,061 Supplemental disclosures of cash flow information: Net cash paid for (received from) income taxes $ ( 278 ) $ 462 Noncash investing and financing activities: Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities $ 118 $ 398 Issuance of Class A common stock for settlement of contingent consideration $ 8,703 $ — The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 7 Table of Contents 10x Genomics, Inc. Notes to Unaudited Condensed Consolidated Financial Statements o 1.     Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. The Company’s integrated research solutions include the Company’s single cell instruments, which include the Company’s Chromium instruments, and the Company's Spatial instruments, which include the Company’s Visium CytAssist and Xenium Analyzer instruments, and the Company’s consumables which include proprietary microfluidic chips, slides, reagents and other consumables for the Company’s Chromium, Visium and Xenium solutions. The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualizatio Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 5. Other Information 22 Item 6. Exhibits 23 Signatures 24 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safe harbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies, acquisition of Scale Biosciences, Inc., results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, plans and expectations regarding entering the clinical and diagnostic markets, the timing and outcome of regulatory filings and approvals, performance and benefits of our products and services, business trends and other information. These statements are based on management’s expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.’s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Genomics, Inc. disclaims any obligation to update any published forward-looking statements except as required by law. The material risks, uncertainties and other factors that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ from those indicated by the forward-looking statements made include those described in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Our periodic filings are accessible on the U.S. Securities and Exchange Commission's (“SEC”) website at www.sec.gov. Although we believe the expectations reflected in the forward-looking statements are reasonable, new risks and uncertainties may emerge, and it is not possible for us to predict their impact on the forward-looking statements contained in this Quarterly Report. Moreover, the information the forward-looking statements are based upon may be limited or incomplete, and may not be based upon all potentially relevant information. We cannot guarantee future events, circumstances, results, performance or achievements. In light of the foregoing, investors are urged not to place undue reliance on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our,” “the Company,” “10x” and similar references refer to 10x Genomics, Inc. and its subsidiaries. 1 Table of Contents Channels for Disclosure of Information Investors and others should note that we may announce material information to the public through filings with the SEC, our website (https://www.10xGenomics.com), press releases, public conference calls, public webcasts and our social media accounts (https://www.linkedin.com/company/10xgenomics, https://X.com/10xGenomics, https://www.facebook.com/10xGenomics, https://bsky.app/profile/10xgenomics.bsky.social and https://www.youtube.com/@10xGenomics_). We use these channels to communicate with our customers and the public about the Company, our products, our services, our financial results, business developments and other matters. We encourage our investors, the media and others to review the information disclosed through such channels as such information could be deemed to be material information. The information on such channels, including on our website and our social media accounts, is not incorporated by reference in this Quarterly Report and shall not be deemed to be incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Please note that this list of disclosure channels may be updated from time to time. 2 Table of Contents 10x Genomics, Inc. PART I—FINANCIAL INFORMATION Item 1.    Financial Statements. 10x Genomics, Inc. Condensed Consolidated Balance Sheets (In thousands) March 31, 2026 December 31, 2025 (Unaudited) (Note 1) Assets Current assets: Cash and cash equivalents $ 490,285 $ 473,966 Marketable securities 49,563 49,443 Accounts receivable, net 39,031 47,013 Other receivables 17,106 35,480 Inventory 53,487 56,341 Prepaid expenses and other current assets 20,261 22,208 Total current assets 669,733 684,451 Property and equipment, net 220,591 226,711 Operating lease right-of-use assets 58,390 60,450 Goodwill 4,511 4,511 Intangible assets, net 59,910 62,329 Other noncurrent assets 2,624 2,913 Total assets $ 1,015,759 $ 1,041,365 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 17,425 $ 12,733 Accrued compensation and related benefits 21,506 42,500 Accrued expenses and other current liabilities 33,680 39,971 Deferred revenue 24,342 23,902 Operating lease liabilities 11,330 10,985 Contingent consideration, current 5,315 23,363 Total current liabilities 113,598 153,454 Contingent consideration, noncurrent 1,222 1,237 Operating lease liabilities, noncurrent 70,059 73,376 Deferred revenue, noncurrent 10,138 10,501 Other noncurrent liabilities 6,418 6,471 Total liabilities 201,435 245,039 Commitments and contingencies (Note 4) Stockholders’ equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 2,338,269 2,306,690 Accumulated deficit ( 1,524,061 ) ( 1,510,591 ) Accumulated other comprehensive income 114 225 Total stockholders’ equity 814,324 796,326 Total liabilities and stockholders’ equity $ 1,015,759 $ 1,041,365 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents 10x Genomics, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) Three Months Ended March 31, 2026 2025 Products and services revenue $ 149,896 $ 137,823 License and royalty revenue 947 17,060 Revenue 150,843 154,883 Cost of products and services revenue 44,665 49,438 Gross profit 106,178 105,445 Operating expenses: Research and development 56,847 64,245 Selling, general and administrative 66,377 89,728 Gain on settlement — ( 9,200 ) Total operating expenses 123,224 144,773 Loss from operations ( 17,046 ) ( 39,328 ) Other income (expense): Interest income 5,014 3,686 Other income (expense), net ( 815 ) 2,136 Total other income 4,199 5,822 Loss before provision for income taxes ( 12,847 ) ( 33,506 ) Provision for income taxes 623 852 Results of Operations 17 Item 3. Quantitative and Qualitative Disclosures about Market Risk 21 Item 4. Controls and Procedures 21 PART II. OTHER INFORMATION 22 Item 1. Legal Proceedings 22 Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 5. Other Information 22 Item 6. Exhibits 23 Signatures 24 Table of Contents 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safe harbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies, acquisition of Scale Biosciences, Inc., results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, plans and expectations regarding entering the clinical and diagnostic markets, the timing and outcome of regulatory filings and approvals, performance and benefits of our products and services, business trends and other information. These statements are based on management’s expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.’s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Genomics, Inc. disclaims any obligation to update any published forward-looking statements except as required by law. The material risks, uncertainties and other factors that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ from those indicated by the forward-looking statements made include those described in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Our periodic filings are accessible on the U.S. Securities and Exchange Commission's (“SEC”) website at www.sec.gov. Although we believe the expectations reflected in the forward-looking statements are reasonable, new risks and uncertainties may emerge, and it is not possible for us to predict their impact on the forward-looking statements contained in this Quarterly Report. Moreover, the information the forward-looking statements are based upon may be limited or incomplete, and may not be based upon all potentially relevant information. We cannot guarantee future events, circumstances, results, performance or achievements. In light of the foregoing, investors are urged not to place undue reliance on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. Unless otherwise stated or the context otherwise indicates, references to “we,” “us,” “our,” “the Company,” “10x” and similar references refer to 10x Genomics, Inc. and its subsidiaries. 1 Table of Contents Channels for Disclosure of Information Investors and others should note that we may announce material information to the public through filings with the SEC, our website (https://www.10xGenomics.com), press releases, public conference calls, public webcasts and our social media accounts (https://www.linkedin.com/company/10xgenomics, https://X.com/10xGenomics, https://www.facebook.com/10xGenomics, https://bsky.app/profile/10xgenomics.bsky.social and https://www.youtube.com/@10xGenomics_). We use these channels to communicate with our customers and the public about the Company, our products, our services, our financial results, business developments and other matters. We encourage our investors, the media and others to review the information disclosed through such channels as

The provided excerpt is only the Form 10‑Q cover page for GE Vernova Inc. (GEV) for quarter ended 2026‑06‑30, with no financial statements, MD&A, segment results, guidance, backlog, risks, or other performance details included. As-is, it contains almost no trade-relevant incremental information beyond confirming the filing/period and listing details.

This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.

The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.

The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).

The provided text is only the cover/header portion of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.

This excerpt is essentially the cover page of CleanSpark, Inc.’s Form 10-Q for the quarter ended March 31, 2026. It contains identifiers (CIK/file no.), listing venue, and security descriptions (common stock and redeemable warrants with specific exercise terms), but no operating/financial results, guidance, risks, or MD&A detail. Actionability is therefore limited to capital-structure/dilution considerations around the listed warrant.

This excerpt of AST SpaceMobile’s 10‑Q is largely SEC cover-page/boilerplate (registrant info, exchange listing, filing compliance) and contains no financial results, guidance, liquidity, risk-factor updates, or operating metrics. As provided, it does not create a clear tradable catalyst beyond confirming continued reporting/listing status.

This excerpt only includes the cover page of Super Micro Computer, Inc.’s Form 10‑Q for the quarter ended March 31, 2026. It confirms the filing, issuer identity, listing (Nasdaq), and ticker (SMCI), but contains no financial results, guidance, risks, or MD&A content to support a directional investment view.